Vector-borne diseases (VBDs) represent a significant public health challenge in India, responsible for substantial morbidity and mortality. This article aims to provide a comprehensive review of VBDs in India, with a focus on understanding their prevalence and developing effective strategies to combat them.
India's diverse topography and climatic conditions contribute to the prevalence of various VBDs. Malaria, dengue, and chikungunya are the most commonly reported, while emerging diseases like Zika and Kala-azar also pose significant threats. The World Health Organization estimates that India accounts for 89% of South-East Asia's VBDs, highlighting the urgency of addressing this issue.
Several factors contribute to the difficulty in managing VBDs in India. These include a lack of public awareness, inadequate health infrastructure, rapid urbanization, and climate change. Additionally, the high genetic variability of vectors and pathogens complicates the development of effective vaccines and therapeutics.
Efforts to control VBDs in India should focus on integrated vector management, including environmental management and biological control methods. Enhanced surveillance systems, community participation, and intersectoral coordination are crucial. Furthermore, investment in research and development for effective vaccines and therapeutics is imperative.
Healthcare professionals play a pivotal role in combating VBDs. They are instrumental in early detection and prompt treatment, reducing disease transmission. Additionally, they can contribute to public health education, promoting preventive measures and improving community engagement in control programs.
Addressing the burden of VBDs in India requires a comprehensive, multi-faceted approach. Understanding the epidemiology, overcoming challenges, and implementing effective control strategies are key. Healthcare professionals, with their unique roles and responsibilities, are critical in this endeavor, underscoring the need for continuous professional development in this area.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation